Notably, clinical evidence indicated that DIDO1 variants correlate with hyperandrogenism and central adiposity in females, while solute carrier family 12 member 5 (SLC12A5) mutations heighten T2DM risk in this population [176]. Here, SLC12A5 is linked to hyperandrogenism.